{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:23:40Z","timestamp":1792268620903,"version":"4.4.0"},"reference-count":142,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic &amp; Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.bmc.2025.118067","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T20:36:25Z","timestamp":1736973385000},"page":"118067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["An overview of small-molecule agents for the treatment of psoriasis"],"prefix":"10.1016","volume":"119","author":[{"given":"Zhiheng","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengqin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4191-7643","authenticated-orcid":false,"given":"Hongliang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2025.118067_b0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40259-022-00569-z","article-title":"Biologic and small-molecule therapies for moderate-to-severe psoriasis: focus on psoriasis comorbidities","volume":"37","author":"Jiang","year":"2023","journal-title":"BioDrugs"},{"key":"10.1016\/j.bmc.2025.118067_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121788","article-title":"RNA sequencing and metabolic analysis of imiquimod-induced psoriasis-like mice with chronic restrain stress","volume":"326","author":"Al Rudaisat","year":"2023","journal-title":"Life Sci"},{"key":"10.1016\/j.bmc.2025.118067_b0015","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/pharmaceutics16010023","article-title":"Phosphodiesterase-4 inhibition in the management of psoriasis","volume":"16","author":"Crowley","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bmc.2025.118067_b0020","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2023.05.059","article-title":"Evidence for a causal association between psoriasis and psychiatric disorders using a bidirectional Mendelian randomization analysis in up to 902,341 individuals","volume":"337","author":"Wang","year":"2023","journal-title":"J Affect Disord"},{"key":"10.1016\/j.bmc.2025.118067_b0025","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/jm0000214","article-title":"New dermatological agents for the treatment of psoriasis","volume":"44","author":"Thacher","year":"2001","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0030","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd1607","article-title":"Psoriasis: emerging therapeutic strategies","volume":"4","author":"Gottlieb","year":"2005","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118067_b0035","doi-asserted-by":"crossref","first-page":"24059","DOI":"10.1038\/srep24059","article-title":"Increased risk of psoriasis due to combined effect of HLA-Cw6 and LCE3 risk alleles in Indian population","volume":"6","author":"Chandra","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmc.2025.118067_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122938","article-title":"An overview of topical lipid-based and polymer-based nanocarriers for treatment of psoriasis","volume":"638","author":"Aziz Hazari","year":"2023","journal-title":"Int J Pharm"},{"key":"10.1016\/j.bmc.2025.118067_b0045","first-page":"8","article-title":"Psoriasis: how pharmacists can help stop the itch","volume":"45","author":"Thaller","year":"2020","journal-title":"U. S. Pharmacist"},{"key":"10.1016\/j.bmc.2025.118067_b0050","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical presentation, and treatment of psoriasis: a review","volume":"323","author":"Armstrong","year":"2020","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bmc.2025.118067_b0055","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bcp.12509","article-title":"Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis","volume":"79","author":"Ternant","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2025.118067_b0060","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/mjd.2003.554","article-title":"Etanercept: An overview","volume":"49","author":"Goffe","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bmc.2025.118067_b0065","article-title":"Infliximab ameliorates tumor necrosis factor-alpha-induced insulin resistance by attenuating PTP1B activation in 3T3L1 adipocytes in vitro","volume":"88","author":"M\u00e9ndez-Garc\u00eda","year":"2018","journal-title":"Exp Immunol"},{"key":"10.1016\/j.bmc.2025.118067_b0070","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-016-0602-3","article-title":"Secukinumab: A review in psoriatic arthritis","volume":"76","author":"Shirley","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2025.118067_b0075","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J Inflamm Res"},{"key":"10.1016\/j.bmc.2025.118067_b0080","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118067_b0085","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s40265-019-01136-7","article-title":"Risankizumab: First Global Approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2025.118067_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14712598.2019.1551354","article-title":"Risankizumab for the treatment of moderate to severe psoriasis","volume":"19","author":"Chiricozzi","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bmc.2025.118067_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107008","article-title":"IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis","volume":"89","author":"Li","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.bmc.2025.118067_b0100","first-page":"7","article-title":"Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis","volume":"6","author":"Montepaone","year":"2014","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.bmc.2025.118067_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2023.104548","article-title":"Breakthroughs and bottlenecks of psoriasis therapy: Emerging trends and advances in lipid based nano-drug delivery platforms for dermal and transdermal drug delivery","volume":"84","author":"Singh","year":"2023","journal-title":"J Drug Delivery Sci Technol"},{"key":"10.1016\/j.bmc.2025.118067_b0110","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118067_b0115","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s13555-017-0205-2","article-title":"Dermatologist and patient preferences in choosing treatments for moderate to severe psoriasis","volume":"7","author":"Alcusky","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.bmc.2025.118067_b0120","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/1346-8138.16746","article-title":"A discrete choice experiment on oral and injection treatment preferences among moderate-to-severe psoriasis patients inJapan","volume":"50","author":"Komine","year":"2023","journal-title":"J Dermatol"},{"key":"10.1016\/j.bmc.2025.118067_b0125","unstructured":"https:\/\/www.clinicaltrials.gov\/."},{"key":"10.1016\/j.bmc.2025.118067_b0130","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.pupt.2010.03.011","article-title":"The preclinical pharmacology of roflumilast \u2013 A selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease","volume":"23","author":"Hatzelmann","year":"2010","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.bmc.2025.118067_b0135","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17460441.2016.1184642","article-title":"The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease","volume":"11","author":"Cazzola","year":"2016","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.bmc.2025.118067_b0140","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1476-5381.2011.01218.x","article-title":"Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease","volume":"163","author":"Rabe","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bmc.2025.118067_b0145","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s13075-015-0771-6","article-title":"Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors","volume":"17","author":"Perez-Aso","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.bmc.2025.118067_b0150","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jdv.18818","article-title":"Pharmacology of orismilast, a potent and selective PDE4 inhibitor","volume":"37","author":"Silverberg","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.bmc.2025.118067_b0155","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4155\/bio-2018-0004","article-title":"Determination of a PDE4 inhibitor Hemay005 in human plasma and urine by UPLC\u2013MS\/MS and its application to a PK study","volume":"10","author":"Liu","year":"2018","journal-title":"Bioanalysis"},{"key":"10.1016\/j.bmc.2025.118067_b0160","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","article-title":"Tapinarof is a natural AhR agonist thatresolves skin inflammation in miceandhumans","volume":"137","author":"Smith","year":"2017","journal-title":"J, Invest Dermatol"},{"key":"10.1016\/j.bmc.2025.118067_b0165","doi-asserted-by":"crossref","first-page":"8973","DOI":"10.1021\/acs.jmedchem.9b00444","article-title":"Highly selective inhibition of tyrosine kinase 2 (TYK2) for the treatment of autoimmune diseases: discovery of the allosteric inhibitor BMS-986165","volume":"62","author":"Wrobleski","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0170","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2017-eular.3809","article-title":"SAT0226\u2005A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2","volume":"76","author":"Catlett","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bmc.2025.118067_b0175","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1021\/jm100181s","article-title":"2-Imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists","volume":"53","author":"Bolli","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0180","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1124\/jpet.110.176487","article-title":"The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation","volume":"337","author":"Piali","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bmc.2025.118067_b0185","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bcp.12129","article-title":"Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study","volume":"76","author":"Brossard","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.bmc.2025.118067_b0190","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/(SICI)1098-2299(19960901)39:1<36::AID-DDR5>3.0.CO;2-L","article-title":"Activation of phosphoinositide breakdown and elevation of intracellular calcium in a rat RBL-2H3 mast cell line by adenosine analogs: Involvement of A3-adenosine receptors?","volume":"39","author":"Shin","year":"1996","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.bmc.2025.118067_b0195","doi-asserted-by":"crossref","first-page":"11027","DOI":"10.1007\/s13277-014-2396-9","article-title":"Mitochondrial and caspase pathways are involved in the induction of apoptosis by IB-MECA in ovarian cancer cell lines","volume":"35","author":"Abedi","year":"2014","journal-title":"Tumor Biol"},{"key":"10.1016\/j.bmc.2025.118067_b0200","doi-asserted-by":"crossref","first-page":"725","DOI":"10.2147\/JEP.S265632","article-title":"Experimental pharmacological management of psoriasis","volume":"13","author":"Campione","year":"2021","journal-title":"J Exp Pharmacol"},{"key":"10.1016\/j.bmc.2025.118067_b0205","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1021\/acs.jmedchem.9b02067","article-title":"Clobetasol propionate is a heme-mediated selective inhibitor of human cytochrome P450 3A5","volume":"63","author":"Wright","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0210","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/11311020-000000000-00000","article-title":"Topical clobetasol propionate in the treatment of psoriasis","volume":"10","author":"Feldman","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.bmc.2025.118067_b0215","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"John","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.bmc.2025.118067_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bmc.2025.118067_b0225","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"Fridman","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.bmc.2025.118067_b0230","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.bmc.2025.118067_b0235","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bmc.2025.118067_b0240","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118067_b0245","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jphs.2016.12.001","article-title":"A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model","volume":"133","author":"Ito","year":"2017","journal-title":"J Pharmacol Sci"},{"key":"10.1016\/j.bmc.2025.118067_b0250","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1021\/acs.jmedchem.7b01598","article-title":"Identification of N-{cis-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A selective JAK1 clinical candidate for the treatment of autoimmune diseases","volume":"61","author":"Vazquez","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0255","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1021\/jm801142b","article-title":"Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)","volume":"51","author":"Jiang","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0260","doi-asserted-by":"crossref","first-page":"4238","DOI":"10.1021\/acs.jmedchem.1c02058","article-title":"Discovery and structural optimization of toddacoumalone derivatives as novel PDE4 inhibitors for the topical treatment of psoriasis","volume":"65","author":"Song","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0265","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acs.jmedchem.6b01634","article-title":"Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin","volume":"60","author":"Jones","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0270","doi-asserted-by":"crossref","first-page":"5579","DOI":"10.1021\/acs.jmedchem.9b00518","article-title":"Structure-aided identification and optimization of tetrahydro-isoquinolines as novel PDE4 inhibitors leading to discovery of an effective antipsoriasis agent","volume":"62","author":"Zhang","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0275","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1021\/acsmedchemlett.0c00082","article-title":"Optimization of nicotinamides as potent and selective IRAK4 inhibitors with efficacy in a murine model of psoriasis","volume":"11","author":"Nair","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113004","article-title":"Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment","volume":"211","author":"Zhang","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0285","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1021\/acs.jmedchem.0c01698","article-title":"Discovery of BMS-986202: A clinical Tyk2 inhibitor that binds to Tyk2 JH2","volume":"64","author":"Liu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0290","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1021\/acsmedchemlett.1c00112","article-title":"Azatricyclic inverse agonists of ROR\u03b3t that demonstrate efficacy in models of rheumatoid arthritis and psoriasis","volume":"12","author":"Liu","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0295","article-title":"SHP2 allosteric inhibitor TK-453 alleviates psoriasis-like skin inflammation in mice via inhibition of IL-23\/Th17 axis","volume":"25","author":"Wang","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.bmc.2025.118067_b0300","doi-asserted-by":"crossref","first-page":"8828","DOI":"10.1021\/acs.jmedchem.2c00422","article-title":"Discovery of an oral, rule of 5 compliant, interleukin 17A protein\u2013protein interaction modulator for the potential treatment of psoriasis and other inflammatory diseases","volume":"65","author":"Andrews","year":"2022","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0305","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.ejmech.2017.12.069","article-title":"Design, synthesis, and biological evaluation of novel catecholopyrimidine based PDE4 inhibitor for the treatment of atopic dermatitis","volume":"145","author":"Purushothaman","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0310","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2025.118067_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127225","article-title":"Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1\/2 inhibitors","volume":"30","author":"Lu","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0320","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2025.118067_b0325","doi-asserted-by":"crossref","first-page":"10959","DOI":"10.1021\/acs.jmedchem.3c00926","article-title":"Progress on the pharmacological targeting of Janus pseudokinases","volume":"66","author":"Henry","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0330","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1021\/acs.jmedchem.8b00917","article-title":"Dual inhibition of TYK2 and JAK1 for the treatment of autoimmune diseases: discovery of ((S)-2,2-difluorocyclopropyl)((1R,5S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)","volume":"61","author":"Fensome","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128728","article-title":"Optimisation of momelotinib with improved potency and efficacy as pan-JAK inhibitor","volume":"66","author":"Desai","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0340","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1021\/jm201454n","volume":"55","author":"William","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0345","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.bmcl.2013.02.012","article-title":"Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome","volume":"23","author":"Lynch","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0350","doi-asserted-by":"crossref","first-page":"4378","DOI":"10.1021\/acs.jmedchem.2c01800","article-title":"Development and therapeutic implications of tyrosine kinase 2 inhibitors","volume":"66","author":"Zhang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0355","doi-asserted-by":"crossref","first-page":"10473","DOI":"10.1021\/acs.jmedchem.3c00600","article-title":"Discovery of a potent and selective tyrosine kinase 2 inhibitor: TAK-279","volume":"66","author":"Leit","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106642","article-title":"Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis","volume":"189","author":"Roskoski","year":"2023","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.bmc.2025.118067_b0365","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40257-022-00720-0","article-title":"Deucravacitinib for the treatment of psoriatic disease","volume":"23","author":"L\u00e9","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.bmc.2025.118067_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115481","article-title":"Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1","volume":"28","author":"Fensome","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128891","article-title":"Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis","volume":"73","author":"Leit","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.126963","article-title":"Efficient synthesis of tert-butyl 3-cyano-3-cyclopropyl-2-oxopyrrolidine-4-carboxylates: Highly functionalized 2-pyrrolidinone enabling access to novel macrocyclic Tyk2 inhibitors","volume":"30","author":"Sasaki","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0385","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1016\/j.bmcl.2017.08.022","article-title":"Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model","volume":"27","author":"Liang","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0390","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejmech.2013.03.070","article-title":"Lead identification of novel and selective TYK2 inhibitors","volume":"67","author":"Liang","year":"2013","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0395","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1021\/acs.jmedchem.5b01857","article-title":"Structure-based design and synthesis of 3-amino-1,5-dihydro-4H-pyrazolopyridin-4-one derivatives as tyrosine kinase 2 inhibitors","volume":"59","author":"Yogo","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0400","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1021\/jm400266t","article-title":"Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors","volume":"56","author":"Liang","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0405","doi-asserted-by":"crossref","first-page":"16106","DOI":"10.1021\/acs.jmedchem.1c01436","article-title":"Discovery of chromane-6-sulfonamide derivative as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor \u03b3t inverse agonist","volume":"64","author":"Chen","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0410","doi-asserted-by":"crossref","first-page":"10976","DOI":"10.1021\/acs.jmedchem.8b00588","article-title":"Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-\u03b3 (ROR\u03b3 or RORc) inhibitors: hits and misses","volume":"61","author":"Pandya","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0415","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13682","article-title":"Pharmacokinetics, safety, and efficacy of cedirogant from phase I studies in healthy participants and patients with chronic plaque psoriasis","volume":"17","author":"Mohamed","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.bmc.2025.118067_b0420","doi-asserted-by":"crossref","unstructured":"Maier CS, Eckert D, Laroux FS, et al. Cedirogant population pharmacokinetics and pharmacodynamic analyses of interleukin-17A inhibition in two phase I studies in healthy participants and participants with moderate to severe psoriasis. Clin Pharmacol Drug Devel 2024, Online ahead of print.","DOI":"10.1002\/cpdd.1377"},{"key":"10.1016\/j.bmc.2025.118067_b0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112536","article-title":"Discovery of carboxyl-containing biaryl ureas as potent ROR\u03b3t inverse agonists","volume":"202","author":"Sun","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114065","article-title":"Discovery of 2H-chromone-4-one based sulfonamide derivatives as potent retinoic acid receptor-related orphan receptor \u03b3t inverse agonists","volume":"229","author":"Chen","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111984","article-title":"Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor \u03b3t inverse agonists for the treatment of autoimmune diseases","volume":"187","author":"Sun","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0440","doi-asserted-by":"crossref","first-page":"10415","DOI":"10.1021\/acs.jmedchem.8b00392","article-title":"Discovery of 3-cyano-N-(3-(1-isobutyrylpiperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C2 inverse agonist","volume":"61","author":"Schnute","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0445","doi-asserted-by":"crossref","first-page":"7796","DOI":"10.1021\/acs.jmedchem.8b00783","article-title":"Potent and orally bioavailable inverse agonists of ROR\u03b3t resulting from structure-based design","volume":"61","author":"Narjes","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0450","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1016\/j.bmcl.2019.06.036","article-title":"Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as ROR\u03b3t inverse agonists","volume":"29","author":"Lu","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0455","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1016\/j.bmcl.2019.06.044","article-title":"Discovery and pharmacological evaluation of indole derivatives as potent and selective ROR\u03b3t inverse agonist for multiple autoimmune conditions","volume":"29","author":"Shaikh","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0460","doi-asserted-by":"crossref","first-page":"9931","DOI":"10.1021\/acs.jmedchem.9b01369","article-title":"Rationally designed, conformationally constrained inverse agonists of ROR\u03b3t\u2014Identification of a potent, selective series with biologic-like in vivo efficacy","volume":"62","author":"Marcoux","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127392","article-title":"Discovery of (3S,4S)-3-methyl-3-(4-fluorophenyl)-4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxyprop-2-yl)phenyl)pyrrolidines as novel ROR\u03b3t inverse agonists","volume":"30","author":"Jiang","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127174","article-title":"Discovery and optimization of new oxadiazole substituted thiazole ROR\u03b3t inverse agonists through a bioisosteric amide replacement approach","volume":"30","author":"Steeneck","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127441","article-title":"Discovery of 2,6-difluorobenzyl ether series of phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfones as surprisingly potent, selective and orally bioavailable ROR\u03b3t inverse agonists","volume":"30","author":"Duan","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0480","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1021\/acs.jmedchem.0c01992","article-title":"Tricyclic-carbocyclic ROR\u03b3t inverse agonists\u2014Discovery of BMS-986313","volume":"64","author":"Yang","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115424","article-title":"Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor \u03b3t (ROR\u03b3t) inverse agonists","volume":"256","author":"Lu","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0490","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1016\/j.bmcl.2015.05.026","article-title":"Discovery of biaryl carboxylamides as potent ROR\u03b3 inverse agonists","volume":"25","author":"Chao","year":"2015","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0495","doi-asserted-by":"crossref","first-page":"8575","DOI":"10.3390\/ijms23158575","article-title":"Vitamin D signaling in psoriasis: pathogenesis and therapy","volume":"23","author":"Bro\u017cyna","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bmc.2025.118067_b0500","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1021\/jm401989c","article-title":"Combination of triple bond and adamantane ring on the vitamin D side chain produced partial agonists for vitamin D receptor","volume":"57","author":"Kudo","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0505","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1021\/acs.jmedchem.8b00337","article-title":"Aromatic-based design of highly active and noncalcemic vitamin D receptor agonists","volume":"61","author":"Gogoi","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0510","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1021\/jm200743p","article-title":"Synthesis and biological activity of 2-(3\u2032-hydroxypropylidene)-1\u03b1-hydroxy-19-norvitamin D analogues with shortened alkyl side chains","volume":"54","author":"Glebocka","year":"2011","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0515","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.bmc.2025.118067_b0520","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.bmc.2025.118067_b0525","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212570","article-title":"Brodalumab in psoriasis: evidence to date and clinical potential","volume":"8","author":"Foulkes","year":"2019","journal-title":"Drugs in Context"},{"key":"10.1016\/j.bmc.2025.118067_b0530","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmc.2025.118067_b0535","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol (Baltimore, Md.: 1950)"},{"key":"10.1016\/j.bmc.2025.118067_b0540","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ejmech.2017.05.034","article-title":"Pharmacophore guided discovery of small-molecule interleukin 15 inhibitors","volume":"136","author":"\u017by\u017cy\u0144ska-Granica","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0545","doi-asserted-by":"crossref","unstructured":"Datta-Mannan A, Regev A, Coutant DE, et al., Tolerability, and pharmacokinetics of an oral small molecule inhibitor of IL-17A (LY3509754): A phase I randomized placebo-controlled study. Clin Pharmacol Therap 2024, Online ahead of print.","DOI":"10.1002\/cpt.3185"},{"key":"10.1016\/j.bmc.2025.118067_b0550","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.jaad.2020.10.085","article-title":"Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor\u2013modulating agent","volume":"84","author":"Bissonnette","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.bmc.2025.118067_b0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114122","article-title":"Identification of triazolopyridine derivatives as a new class of AhR agonists and evaluation of anti-psoriasis effect in a mouse model","volume":"231","author":"Tian","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0560","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15931","article-title":"Tapinarof for the treatment of psoriasis","volume":"35","author":"Nogueira","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.bmc.2025.118067_b0565","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s40265-022-01748-6","article-title":"Tapinarof cream 1%: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2025.118067_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129383","article-title":"Discovery of 5-((1H-indazol-3-yl) methylene)-2-thioxoimidazolidin-4-one derivatives as a new class of AHR agonists with anti-psoriasis activity in a mouse model","volume":"92","author":"Zhang","year":"2023","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115606","article-title":"The recent advance of Interleukin-1 receptor associated kinase 4 inhibitors for the treatment of inflammation and related diseases","volume":"258","author":"Bai","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0580","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/acs.jmedchem.3c01714","article-title":"Discovery of IRAK4 inhibitors BAY1834845 (Zabedosertib) and BAY1830839","volume":"67","author":"Bothe","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0585","doi-asserted-by":"crossref","first-page":"14564","DOI":"10.1021\/acs.jmedchem.3c01011","article-title":"Discovery of 3-phenyl indazole-based novel chemokine-like receptor 1 antagonists for the treatment of psoriasis","volume":"66","author":"Ko","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115622","article-title":"The design, synthesis and evaluation of 2-aminobenzoxazole analogues as potent and orally efficacious ChemR23 inhibitors","volume":"28","author":"Imaizumi","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115091","article-title":"The discovery and optimization of a series of 2-aminobenzoxazole derivatives as ChemR23 inhibitors","volume":"27","author":"Imaizumi","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0600","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1080\/13543784.2023.2242767","article-title":"Psoriasis: a focus on upcoming oral formulations","volume":"32","author":"Rusi\u00f1ol","year":"2023","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2025.118067_b0605","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.bmc.2025.118067_b0610","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jdermsci.2017.11.003","article-title":"Modeling clinical efficacy of the S1P receptor modulator ponesimod in psoriasis","volume":"89","author":"Krause","year":"2018","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.bmc.2025.118067_b0615","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/jdv.19811","article-title":"Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1)","volume":"38","author":"Papp","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.bmc.2025.118067_b0620","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.3390\/biom12081153","article-title":"Heat shock protein 90 (Hsp90) and Hsp70 as potential therapeutic targets in autoimmune skin diseases","volume":"12","author":"Tukaj","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bmc.2025.118067_b0625","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5114\/ada.2021.106210","article-title":"Does HSP90 play an important role in psoriasis?","volume":"38","author":"Czajkowski","year":"2021","journal-title":"Adv Dermatol Allergol\/post\u0119py Dermatologii i Alergologii"},{"key":"10.1016\/j.bmc.2025.118067_b0630","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1128897","article-title":"Heat shock protein 90 inhibitor RGRN-305 potently attenuates skin inflammation","volume":"14","author":"Ben Abdallah","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmc.2025.118067_b0635","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bjd.20880","article-title":"HSP90 inhibitor RGRN\u2010305 for oral treatment of plaque\u2010type psoriasis: efficacy, safety and biomarker results in an open\u2010label proof\u2010of\u2010concept study","volume":"186","author":"Bregnh\u00f8j","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.bmc.2025.118067_b0640","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40257-016-0179-3","article-title":"Novel oral therapies for psoriasis and psoriatic arthritis","volume":"17","author":"Yiu","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.bmc.2025.118067_b0645","doi-asserted-by":"crossref","first-page":"15205","DOI":"10.1021\/acs.jmedchem.3c01297","article-title":"Design, synthesis, and biological evaluation of an orally bioavailable, potent, and selective ROCK2 inhibitor for psoriasis treatment","volume":"66","author":"Huang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0650","article-title":"Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease","volume":"70","author":"Ali","year":"2022","journal-title":"Curr Res Transl Med"},{"key":"10.1016\/j.bmc.2025.118067_b0655","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/MBC.0b013e32830b2891","article-title":"Comparative gene expression profiling in three primary human cell lines after treatment with a novel inhibitor of Rho kinase or atorvastatin","volume":"19","author":"Boerma","year":"2008","journal-title":"Blood Coagul Fibrinol"},{"key":"10.1016\/j.bmc.2025.118067_b0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116015","article-title":"Discovery of benzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivatives as orally available bromodomain and extra-terminal domain (BET) inhibitors with efficacy in an in vivo psoriatic animal model","volume":"34","author":"Sato","year":"2021","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0665","doi-asserted-by":"crossref","first-page":"10824","DOI":"10.1021\/acs.jmedchem.3c01028","article-title":"Discovery of a bromodomain and extra terminal domain (BET) inhibitor with the selectivity for the second bromodomain (BD2) and the capacity for the treatment of inflammatory diseases","volume":"66","author":"Wang","year":"2023","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0670","doi-asserted-by":"crossref","first-page":"8293","DOI":"10.1021\/acs.jmedchem.6b00604","volume":"59","author":"Li","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0675","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bmc.2017.07.054","article-title":"Discovery and process development of a novel TACE inhibitor for the topical treatment of psoriasis","volume":"26","author":"Boiteau","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0680","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.bmcl.2017.02.035","article-title":"Identification of novel TACE inhibitors compatible with topical application","volume":"27","author":"Ouvry","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmc.2025.118067_b0685","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/1744666X.2016.1204232","article-title":"Therapeutic targeting of Toll-like receptors: a review of Toll-like receptors and their signaling pathways in psoriasis","volume":"12","author":"Rahmani","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.bmc.2025.118067_b0690","doi-asserted-by":"crossref","first-page":"9279","DOI":"10.1021\/acs.jmedchem.1c00532","article-title":"Systematic optimization of potent and orally bioavailable purine scaffold as a dual inhibitor of Toll-like receptors 7 and 9","volume":"64","author":"Kundu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0695","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1021\/acs.jmedchem.0c00011","article-title":"A chemical switch for transforming a purine agonist for toll-like receptor 7 to a clinically relevant antagonist","volume":"63","author":"Mukherjee","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0700","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1021\/acs.jmedchem.0c00055","article-title":"Identification of N-phenyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as novel, potent, and selective NF-\u03baB Inducing kinase (NIK) inhibitors for the treatment of psoriasis","volume":"63","author":"Zhu","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0705","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.03.073","article-title":"Synthesis and identification of quinoline derivatives as topoisomerase I inhibitors with potent antipsoriasis activity in an animal model","volume":"88","author":"Zhang","year":"2019","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2025.118067_b0710","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/08923973.2013.862542","article-title":"A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model","volume":"36","author":"Sun","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"}],"container-title":["Bioorganic &amp; Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089625000082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:22:33Z","timestamp":1740460953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089625000082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":142,"alternative-id":["S0968089625000082"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118067","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An overview of small-molecule agents for the treatment of psoriasis","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2025.118067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118067"}}